Valuations of Early-Stage Companies and Disruptive Technologies (eBook)

How to Value Life Science, Cybersecurity and ICT Start-ups, and their Technologies

Tiran Rothman (Autor)

eBook Download: PDF

2020 | 1st ed. 2020
XII, 219 Seiten
Springer International Publishing (Verlag)
978-3-030-38847-8 (ISBN)

Infos

This book will serve as a practical guide for entrepreneurs and investors/advisors in constructing and understanding valuations of startups in rapidly shifting industries, including the areas of drug development, medical devices, cyber security, and renewable energy. For large companies, valuation is based on forecasts of free cash flow; in technologically-driven industries, product pipelines can represent a large part of market capitalization. The situation is even more critical for small companies committed to a single idea: all of their value is linked to a single project. Any business transaction or internal proposal to begin or terminate an R&D project in which innovative projects are being valued or exchanged requires a realistic valuation of those projects. Moreover, different projects have very different dynamics. Pharmaceuticals have very large lead times and are dependent on patents as well as out-licensing agreements. In contrast, software develops very quickly, and IP is hard to value. This book will be a guide to building appropriate valuations for companies competing in rapidly shifting industries and offering products under new business models where little precedent exists, taking both financial and behavioral issues into consideration.

Tiran Rothman has over a decade of experience in financial consultancy and academic and applied research in behavioral finance and economics. As a vice president of Frost & Sullivan, he leads the largest private financial valuation program for high-tech companies and the Tel Aviv Stock Exchange Equity Research Program, involving pharmaceutical, biotechnology, medical device, ICT, renewable energy, autonomous vehicle and cybersecurity companies. He previously served as the Chief Economist of AMPAL (NASDAQ: AMPL). Tiran is also an Assistant Professor at the WIZO Academic Center Haifa in Israel. He holds a PhD in Behavioral Economics from the University of Haifa, an MBA in Finance from IDC Herzliya and was a visiting fellow at New York University's Stern Business School. He has published widely in the field of behavioral finance and has been the recipient of numerous research grants and scholarships.

Produkt-Details

• Erscheint lt. Verlag: 27.11.2020
• Zusatzinfo: XII, 219 p. 11 illus., 5 illus. in color.
• Sprache: englisch
• Themenwelt: Sozialwissenschaften ► Politik / Verwaltung
• Themenwelt: Wirtschaft ► Betriebswirtschaft / Management ► Logistik / Produktion
• Themenwelt: Wirtschaft ► Betriebswirtschaft / Management ► Unternehmensführung / Management
• Schlagworte: biotech projects • Corporate value • cybersecurity companies • Discounted Cash Flow • Disruptive industries • Disruptive Technologies • Early stage valuations • Equity Valuation • Innovative Companies • investor/entrepreneur behavior • pharma companies • Start-up Valuation • Valuing disruptive start-ups
• ISBN-10: 3-030-38847-6 / 3030388476
• ISBN-13: 978-3-030-38847-8 / 9783030388478